Pfizer's Investigational Drug Flunks Late-Stage For Sickle Cell Disease

Pfizer Inc. (NYSE:PFE) on Friday released results from the Phase 3 THRIVE-131 study evaluating inclacumab, an investigational P-selectin inhibitor, in patients 16 years of age and older with sickle cell disease.

PFE shares are consolidating after recent moves. Track the latest developments here.

Sickle cell disease is a group of inherited red blood cell disorders that affects hemoglobin, the protein that carries oxygen. It causes red blood cells to become rigid and sickle-shaped, leading to blocked blood flow, pain and organ damage. 

The study did not meet its primary endpoint of a significant reduction in the rate of vaso-occlusive crises (VOCs) in participants receiving inclacumab versus placebo every 12 weeks over 48 weeks.

Inclacumab was generally well-tolerated in THRIVE-131.

The most commonly